Pfizer Inc., US7170811035

Pfizer raises 2026 revenue guidance: Pfizer stock loses 1.08 percent

Published on 10/02/2026 at 16:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Q2 revenue reached USD 15.03 billion and adjusted EPS was USD 0.77. Pfizer stock costs EUR 24.74 on October 2, 2026 after EUR 25.01.
Pfizer Inc., US7170811035, Illustration mit AI erstellt.

Pfizer Inc. (ISIN US7170811035) was trading at EUR 24.74 at Lang & Schwarz on October 2, 2026 at 4:38 p.m. CEST, down 1.08 percent from the prior close of EUR 25.01. The company raised its full-year 2026 revenue guidance midpoint by USD 500.0 million to USD 60.5 billion-USD 62.5 billion, according to ScanX News on September 28, 2026.

Guidance rises on non-COVID products

The updated revenue range compares with the previous USD 59.5 billion-USD 60.5 billion range. ScanX News reported that adjusted diluted earnings per share guidance remained USD 2.80-USD 3.00 for full-year 2026, while second-quarter adjusted diluted earnings per share reached USD 0.77.

Second-quarter 2026 revenue was USD 15.03 billion, up 1.00 percent operationally from a year earlier, according to Zacks on October 1, 2026. The comparison matters because the higher guidance midpoint relies on non-COVID products offsetting weaker COVID-related revenue and patent-cliff pressure.

Analyst target stays below market price

UBS maintained a Hold rating and a USD 27.00 price target for Pfizer in a report released October 2, 2026, as Markets Insider reported. Pfizer's euro quote cannot be compared mathematically with that dollar target, but the differing currencies underline why the Lang & Schwarz price is the relevant reference for German investors.

Market data put Pfizer's NYSE 52-week range at USD 23.62-USD 29.21 on October 2, 2026, with a market capitalization of USD 158.7 billion. The current euro quote sits between those dollar levels only as separate venue context, not as a currency conversion.

Next results date is November 3

Pfizer's next earnings report is scheduled for November 3, 2026, according to TradingView. That date gives investors a defined checkpoint for testing whether the stronger non-COVID portfolio can support the higher annual revenue range while adjusted earnings guidance remains unchanged.

Stock trades below prior close

Pfizer was trading at EUR 24.74 at Lang & Schwarz on October 2, 2026 at 4:38 p.m. CEST, minus 1.08 percent versus the Lang & Schwarz prior close of EUR 25.01 on October 1, 2026. The further course of trading is shown by the continuously updated real-time quote of Pfizer stock.

Pfizer stock facts

  • Company: Pfizer Inc.
  • ISIN: US7170811035
  • WKN: 852009
  • Ticker: PFE
  • Primary exchange: NYSE
  • Price Lang & Schwarz as of October 2, 2026, 4:38 p.m. CEST: EUR 24.74
  • Change versus prior close: minus 1.08 percent
  • Prior close Lang & Schwarz October 1, 2026: EUR 25.01
  • Market capitalization: USD 158.7 billion (as of October 2, 2026)
  • 52-week range: USD 23.62-USD 29.21 (as of October 2, 2026)
  • Sector / Industry: Healthcare / Drug Manufacturers - General
  • Next earnings date: November 3, 2026

More news and analyses on Pfizer stock

Disclaimer...
en | US7170811035 | PFIZER INC. | boerse | 70216365 | bgmi